Please login to the form below
heart failure
This page shows the latest heart failure news and features for those working in and with pharma, biotech and healthcare.
FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
Hypertrophic cardiomyopathy (HCM) is a chronic and progressive disease which causes excessive contraction of the heart muscles and reduces the ability of the left ventricle to fill. ... In both obstructive or non-obstructive HCM patients, physical
Latest news
-
AZ forecasts growth in 2021 after revenues surge in Q4
That growth was led by an increase in revenue for AZ’s heart failure treatment Farxiga (dapagliflozin), which saw a 27% increase in 2020 to $1.96bn.
-
Novartis hit by ‘COVID-19-related lockdowns’ in Q4
added. In the Q4 results, Novartis highlighted its main growth drivers – including its heart failure drug Entresto (sacubitril/valsartan), its immunology therapy Cosentyx (secukinumab) and its spinal muscular atrophy (SMA) gene
-
Bayer strengthens cell and gene therapy focus with new platform
heart failure.
-
AZ divests European rights for cholesterol med Crestor to Grünenthal
In October, AZ also divested the commercial rights to its heart failure and hypertension treatments Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in
-
Novartis weathers the COVID-19 storm in Q3, lifts outlook
Novartis’ main growth drivers, and protectors against the continuing impact caused by the COVID-19 pandemic, includes its spinal muscular atrophy (SMA) gene therapy Zolgensma and chronic heart failure med Entresto
More from news
Approximately 46 fully matching, plus 254 partially matching documents found.
Latest Intelligence
-
Understand, identify and partner with HCPs to improve patient support
patients are at risk of heart failure or stroke.
-
AI and accelerated computing ring in new era for healthcare
The typical drug discovery process takes about a decade, costs $2bn and suffers a 90% failure rate during clinical development. ... The project is initially connecting four of London’s premier teaching hospitals, offering AI services to accelerate work
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
heart failure also have CKD.
-
20 for 2020 – Five pharma leaders to watch in 2020
Hudson had a distinguished career at Novartis, presiding over the launches and roll-outs of psoriasis blockbuster Cosentyx (secukinumab), spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec) and heart failure therapy
-
20 for 2020 – Five pharma companies to watch
Diabetes therapy Farxiga (dapagliflozin) has the potential to go where no other drug in the SGLT2 inhibitor class has gone before as it secures approval for heart failure in both diabetic
More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest appointments
-
uniQure appoints chief executive officer
for congestive heart failure and Huntington's disease into the clinic.”.
-
Cardio3 BioSciences appoints Warren Sherman chief medical officer
Sherman has over 30 years' cardiology experience, with a focus on cell-based therapies for treating patients post-myocardial infarction and with heart failure.
-
Acorda appoints new CFO
pain and heart failure. .
-
Cardioxyl appoints Novartis scientist as chief medical officer
Dr Foo was responsible for the establishment and execution of multiple programmes in heart failure and the cardiorenal space at Novartis and will use her experience to lead research at ... Her unique combination of both early- and late-stage
-
CytomX makes senior changes following Pfizer deal
Prior to this period at Affymax, Dr Polu was executive director, global development at Amgen, where he worked in the development of products in nephrology, diabetes and heart failure.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Live Webinar: Nanobiotechnology, Artificial Intelligence, and Virtual Care
technology, AI, and deep-learning-enabled diagnostics for remote monitoring of congestive heart failure, chronic diseases, and COVID-19.
-
New from the FDA: Diversity in clinical trials guidance summarised
For example, if those with advanced heart failure were unable to participate, would it be the same for those with a milder condition? ... Is it necessary to exclude all people with varying degrees of heart failure?
-
What is changing in cardiovascular disease care?
Introduction. Cardiovascular disease (CVD), which covers a wide range of conditions, such as coronary heart disease, heart valve disease (HVD) and strokes, is responsible for a quarter of all deaths in ... Integrated care organisations. Many CVD
-
What is changing in mental health and dementia care?
From 2020/21, PCNs will use digital health records and health management tools to identify moderate frailty and detect and intervene to treat undiagnosed disorders, such as heart failure.
-
ECHO Medical Communications
ECHO delivers dedicated medical communications specialising in the areas of endocrinology, cardiovascular disease, heart failure and obesity.
More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Associate Account Director
-
Competitive Salary
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Senior Account Executive
-
Competitive Salary
-
Medical Editor
-
Competitive Salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Medical Writer
-
Competitive Salary
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
-
Account Manager
-
Competitive Salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Roche’s Ocrevus shows significant benefit in early-stage MS patients
- Roche reports strong diagnostics sales in Q1 as demand for COVID-19 tests continues
- EMA finds overall benefit-risk ‘remains positive’ for J&J COVID-19 vaccine
- Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
- Health leaders welcome EDPB’s opinion on adequacy of UK’s data protection standards
- bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021
- Havas Health & You appoints Pat Thistlethwaite as chief experience officer
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Empowering patients empowers results
- Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
- Don’t limit diversity to just representation in clinical trials
- What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
- Oh no… not more training
- Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
Quick links
Infographics
